Quiroz Jose, Yazdanyar Amirfarbod
Medical Scientist Training Program, Albert Einstein College of Medicine, Bronx, NY, USA.
Department of Ophthalmology and Visual Sciences, State University of New York (SUNY), Upstate Medical University, Syracuse, NY, USA.
Ann Transl Med. 2021 Aug;9(15):1272. doi: 10.21037/atm-20-6737.
The retina is the posterior neuro-integrated layer of the eye that conducts impulses induced by light to the optic nerve for human vision. Diseases of the retina often leads to diminished vision and in some cases blindness. Diabetes mellitus (DM) is a worldwide public health issue and globally, there is an estimated 463 million people that are affected by DM and its consequences. Diabetic retinopathy (DR) is a blinding complication of chronic uncontrolled DM and is the most common cause of blindness in the United States between the ages 24-75. It is estimated that the global prevalence of DR will increase to 191.0 million by 2030, of those 56.3 million possessing vision-threatening diabetic retinopathy (VTDR). For the most part, current treatment modalities control the complications of DR without addressing the underlying pathophysiology of the disease. Therefore, there is an unmet need for new therapeutics that not only repair the damaged retinal tissue, but also reverse the course of DR. The key element in developing these treatments is expanding our basic knowledge by studying DR pathogenesis in animal models of proliferative and non-proliferative DR (PDR and NPDR). There are numerous models available for the research of both PDR and NPDR with substantial overlap. Animal models available include those with genetic backgrounds prone to hyperglycemic states, immunologic etiologies, or environmentally induced disease. In this review we aimed to comprehensively summarize the available animal models for DR while also providing insight to each model's ocular therapeutic potential for drug discovery.
视网膜是眼睛后部的神经整合层,它将光诱导产生的冲动传导至视神经,以实现人类视觉。视网膜疾病常常导致视力下降,在某些情况下会导致失明。糖尿病是一个全球性的公共卫生问题,据估计,全球有4.63亿人受到糖尿病及其后果的影响。糖尿病视网膜病变(DR)是慢性未控制糖尿病的一种致盲并发症,是美国24至75岁人群中最常见的失明原因。据估计,到2030年,全球DR患病率将增至1.91亿,其中5630万人患有威胁视力的糖尿病视网膜病变(VTDR)。在很大程度上,目前的治疗方式控制了DR的并发症,但并未解决该疾病的潜在病理生理学问题。因此,迫切需要新的治疗方法,不仅能修复受损的视网膜组织,还能逆转DR的病程。开发这些治疗方法的关键要素是通过研究增殖性和非增殖性DR(PDR和NPDR)动物模型中的DR发病机制来扩展我们的基础知识。有许多模型可用于PDR和NPDR的研究,且有大量重叠。可用的动物模型包括那些具有易患高血糖状态的遗传背景、免疫病因或环境诱导疾病的模型。在本综述中,我们旨在全面总结现有的DR动物模型,同时也深入了解每个模型在药物发现方面的眼部治疗潜力。